SCL Healthcare announced on the 18th that it has obtained a U.S. patent for a technology that predicts, through genetic testing, the risk of high blood expression of ceramide—regarded as a key cause of metabolic syndrome.

The patented technology uses 12 single nucleotide polymorphism (SNP) markers identified through a genome-wide association study (GWAS) to enable early prediction of an individual’s risk of developing metabolic syndrome and the likelihood of high blood ceramide expression. The company explained that disease risk can be assessed solely through genetic testing before full-scale onset, and that the technology can also be used for precision diagnosis by analyzing detailed ceramide types.

Metabolic syndrome is a condition in which abdominal obesity, hypertension, hyperglycemia, and dyslipidemia appear together, and if left untreated, it is known to increase the risk of type 2 diabetes and cardiovascular disease. Recently, ceramide has attracted attention as one of the key factors that induce metabolic disorders by increasing insulin resistance, further underscoring the importance of early prediction and prevention.

SCL Healthcare assessed that registration of the U.S. patent confirms the originality and advancement of this technology in the world’s largest biohealth market. The company plans to expand application of the technology to early prediction and diagnostic kits for metabolic syndrome, risk prediction services linked to health checkups, and companion diagnostic biomarkers for new drug clinical trials.

An SCL Healthcare representative stated, “We will accelerate commercialization so that we can provide customers with high-quality metabolic disease prediction services as quickly as possible.”

Popular News